Analysis

Gilead Sciences, Inc. (GILD) Stock Analysis

Gilead Sciences, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to GILD.

websiteGILD/analysis/GILD

Gilead Sciences, Inc.

Gilead Sciences, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to GILD.

Stock profile

Ticker

GILD

Asset type

Stock

Market cap

$153.66B

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Gilead Sciences, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • GILD primary listing
  • GIS
  • 1GILD
  • 885823
  • GILDD
  • GILD34
  • 0QYQ
  • 4GILD

Latest Gilead Sciences, Inc. news

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for...

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Preven...

FOSTER CITY, Calif., June 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Applicati...

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Tr...

FOSTER CITY, Calif., & RAHWAY, N.J., June 08, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today annou...

Research sections

Valuation

Review valuation context for Gilead Sciences, Inc..

Future growth

Review future growth context for Gilead Sciences, Inc..

Past performance

Review past performance context for Gilead Sciences, Inc..

Financial health

Review financial health context for Gilead Sciences, Inc..

Dividend

Review dividend context for Gilead Sciences, Inc..

Management

Review management context for Gilead Sciences, Inc..

Ownership

Review ownership context for Gilead Sciences, Inc..

Other information

Review other information context for Gilead Sciences, Inc..

Community

Review community context for Gilead Sciences, Inc..